Collaborations - Additional Information (Details) - USD ($) $ in Thousands				1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 25, 2025	Jul. 07, 2020	May 09, 2019	Jun. 30, 2025	Jun. 30, 2025	Dec. 31, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue Recognized							$ 75,000
Cost reimbursement payment received							1,300	$ 8,800
Unbilled accounts receivable							0	900
Private placement, net of issuance costs								14,877
Revenue recognized							39,211	47,072	$ 78,592
Research and development							316,568	240,248	189,081
Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue							23,600
Unconstrained consideration						$ 55,000			55,000
Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized							19,400
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment		$ 150,000
Collaboration agreement transaction price		150,000
Revenue recognized recorded in deferred revenue							33,600	13,600
Unsatisfied performance obligation						54,700		13,600	54,700
Unconstrained consideration							20,000
Sanofi Agreement | Milestone 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized						40,000
Sanofi Agreement | Milestone 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestones Revenue Recognized						$ 15,000
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		120,000
Revenue recognized recorded in deferred revenue									67,700
Revenue recognized							33,600	47,100	70,200
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		30,000
Revenue recognized recorded in deferred revenue									2,500
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments		1,480,000		$ 975,000
Commercial milestone payments		$ 700,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial research term of collaboration			4 years
Extended research term of collaboration			1 year
Revenue recognized							0	0	8,400
Vertex Agreement | Series B-1 Convertible Preferred
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price			$ 55,900
Non refundable upfront payment received			$ 50,000
Issuance of shares, Shares			3,059,695
Preferred stock premium			$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones			$ 170,000
Gilead Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 40,000
Option exercise payment	45,000
Collaboration agreement transaction price							40,000
Revenue recognized recorded in deferred revenue							34,400	0
Increase in Revenue					$ 40,000
Deferred revenue							$ 34,400
Remaining research term of collaboration							1 year 3 months 18 days
Revenue recognized							$ 5,600	$ 0	$ 0
Gilead Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payments	$ 665,000